CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Review CIRB
Study Status
Study Number Sort descending Lead Group Study Title CIRB Study Status
S2308 SWOG Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma Adult CIRB - Late Phase Emphasis Available to Open
S2312 SWOG A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature Adult CIRB - Late Phase Emphasis Available to Open
S9910 SWOG Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary Adult CIRB - Late Phase Emphasis Completed
S9925 SWOG Lung Cancer Specimen Repository Protocol Ancillary Adult CIRB - Late Phase Emphasis Completed
SCUSF-0901 COG SCUSF 0901 [ACCL0922] A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor Pediatric CIRB Available to Open
SWOG-9007 SWOG Cytogenetic Studies in Leukemia Patients Adult CIRB - Late Phase Emphasis Completed
TRC-10446 NCI Tocilizumab in Hospitalized Cancer Patients with Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19) Adult CIRB - Late Phase Emphasis Completed
UAZ20-01-01 CP-CTNet_CLO-University of Arizona Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy Cancer Prevention and Control CIRB Available to Open
UAZ20-01-02 CP-CTNet_CLO-University of Arizona An extended follow-up study of the HPV vaccine delayed booster trial Cancer Prevention and Control CIRB Available to Open
UAZ2015-05-01 CP-CTNet_CLO-University of Arizona A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys Cancer Prevention and Control CIRB Available to Open